InMed’s scientific team has developed IntegraSyn™ – a flexible, high yield and cost-effective manufacturing system to produce pharmaceutical-grade, bio-identical cannabinoids. InMed recently announced that IntegraSyn™ has achieved a cannabinoid yield of 5 g/L, a commercially viable yield that significantly exceeds currently reported industry yields.
How does IntegraSyn™ work?
- IntegraSyn™ integrates well-established manufacturing processes such as biosynthesis, biotransformation and other traditional pharmaceutical manufacturing methods.
- IntegraSyn™ optimizes use of expensive manufacturing steps, using sophisticated, but cost efficient starting materials.
- IntegraSyn™ allows for flexibly shifting from production of one cannabinoid to a range of others, providing improved yields.
- And IntegraSyn™ is designed to be scalable and to produce the consistent, compliant, highly pure cannabinoids required for pharmaceutical products.
As interest in the therapeutic potential of cannabinoids continues to grow, IntegraSyn™ may be the solution to provide access to a range of cost-effective, bio-identical cannabinoids.